Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gadoquatrane vs macrocyclic GBCAs for CNS MRI
2022-501884-41-00Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of gadoquatrane in Central nervous system pathology requiring contrast-enhanced magnetic resonance imaging (2 arms), sponsored by Bayer. Started Sep 2023; status: completed.
02
Drugs
gadoquatrane
03
Conditions
Central nervous system pathology requiring contrast-enhanced magnetic resonance imaging
Beyond the preview
Go deeper on 2022-501884-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501884-41-00.